Payment overview · 2025
General Payments
$656.23
37 reported records · 18 companies
Healthcare provider profile · identity verified
Andrew Thayne, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · POCATELLO, ID · NPI 1669405791
Verified facts
What the public records show
CMS Open Payments records show Andrew Thayne, M.D. received $656.23 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.78 | 21.4% | 9 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.82 | 15.1% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $45.66 | 7.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.11 | 6.4% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $32.23 | 4.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.12 | 4.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.14 | 4.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.28 | 4.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.46 | 4.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.85 | 3.9% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.87 | 3.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.81 | 3.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $18.29 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.88 | 2.7% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $17.44 | 2.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.15 | 2.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.23 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.11 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $656.23 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $98.82 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $81.52 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.26 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.59 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $45.66 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $42.11 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.14 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.14 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.28 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.28 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.85 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 99 |
| Omeprazole | Omeprazole | 354 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 285 | 42 |
| Losartan Potassium | Losartan Potassium | 270 | 75 |
| Lisinopril | Lisinopril | 243 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 63 |
| Metformin Hcl Er | Metformin Hcl | 215 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 43 |
| Metformin Hcl | Metformin Hcl | 165 | 41 |
| Meloxicam | Meloxicam | 163 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 157 | 41 |
| Gabapentin | Gabapentin | 131 | 36 |
| Trazodone Hcl | Trazodone Hcl | 121 | 38 |
| Simvastatin | Simvastatin | 117 | 35 |
| Lorazepam | Lorazepam | 109 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 24 |
| Furosemide | Furosemide | 99 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 25 |
| Tramadol Hcl | Tramadol Hcl | 87 | 22 |
| Warfarin Sodium | Warfarin Sodium | 84 | 17 |
| Allopurinol | Allopurinol | 83 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 29 |
| Potassium Chloride | Potassium Chloride | 82 | 24 |
| Eliquis | Apixaban | 76 | 14 |
| Sertraline Hcl | Sertraline Hcl | 74 | 20 |
| Estradiol | Estradiol | 73 | 22 |
| Ozempic | Semaglutide | 68 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 18 |
| Prednisone | Prednisone | 65 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 17 |
| Spironolactone | Spironolactone | 63 | 21 |
| Buspirone Hcl | Buspirone Hcl | 58 | 19 |
| Celecoxib | Celecoxib | 54 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 12 |
| Cephalexin | Cephalexin | 52 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Azithromycin | Azithromycin | 48 | 42 |
| Alprazolam | Alprazolam | 47 | suppressed |
| Gemfibrozil | Gemfibrozil | 46 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Alendronate Sodium | Alendronate Sodium | 43 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 12 |
| Finasteride | Finasteride | 37 | 12 |
| Glipizide Er | Glipizide | 37 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 20 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 12 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Procto-Med Hc | Hydrocortisone | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $656.23 · 37 records | ABBVIE INC. | AUSTEDO XR, CAPVAXIVE, Cologuard Collection Kit, ENFLONSIA, FANAPT, GARDASIL 9, GEMTESA, INGREZZA, INSPIRE, Kerendia, M-M-R II, MOUNJARO, OTEZLA, Ocrevus Zunovo, Ozempic, QULIPTA, QUTENZA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, YUPELRI, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error